by Mary Ann Liebert, Inc

Determination of the longest effective time of IMP treatment post-injury. (A, B) Ladder rung results from 1-week (A) and 3-weeks (B) post-injury where the total number of foot falls is divided by total number of steps. (C) 20 × magnification representative images of legion 5 weeks post-injury. (D) Average lesion volumes of cortical tissue 5 weeks following injury. n = 5 except for the saline group n = 8. Data are means ±SEM. *p < 0.05, **p < 0.01, ***p < 0.05, ****p < 0.01 by ANOVA with the Tukey post hoc test. IMP, immunomodulatory nanoparticle; ANOVA, one-way analysis of variance. Credit: Journal of Neurotrauma (2024). DOI: 10.1089/neu.2024.0218

A new study published in the Journal of Neurotrauma shows that intravenous administration of immunomodulatory nanoparticles after traumatic brain injury (TBI) can limit the development of an inflammatory cascade that typically leads to substantial secondary damage. The nanoparticles limited inflammatory cell infiltration and reduced both behavioral decline and lesion size without any noticeable toxicity in mice.

John Kessler, MD, from Northwestern University, and co-authors, demonstrated that there is a dose-response relationship between the amount of immunomodulatory nanoparticle administered and tissue damage.

“There is a therapeutic window of efficacy for nanoparticle administration of at least 6 hours after injury with some benefit observed when treatment was delayed for 12 hours after injury,” stated the investigators.

“Immunomodulatory nanoparticles are non-toxic and are made of an FDA-approved material that is stable at room temperature,” stated the investigators.

“They could easily be given intravenously immediately after TBI on the field by emergency medical technicians or in the emergency room to prevent secondary damage, thereby improving outcome.”

“This is an intriguing paper from Dr. Bertossi and colleagues. Immunomodulatory nanoparticles are a relatively new class of candidate therapeutics and we should all read this paper carefully. I was especially pleased to see that the therapeutic window extended out to at least 6 hours in the mouse controlled cortical impact injury model.

“Blinding and randomization were solid and statistical power calculations were used to determine sample size, in concordance with best transparency, rigor and reproducibility practices. We’re all looking forward to seeing what happens next,” says David L. Brody, MD, Ph.D., Editor-in-Chief of Journal of Neurotrauma.

More information: Ryan Bertossi et al, Intravenous Immunomodulatory Nanoparticles Prevent Secondary Damage after Traumatic Brain Injury, Journal of Neurotrauma (2024). DOI: 10.1089/neu.2024.0218

Journal information:Journal of Neurotrauma

Provided by Mary Ann Liebert, Inc

---

Explore further

Improving functional recovery of the brain and heart after traumatic brain injury

ReplyReply to allForward